Cambridge Healthtech Institute’s 5th Annual

Preclinical and Translational Immuno-Oncology

Predictive Preclinical Models and Translational Strategies for Cancer Immunotherapy

August 11-12, 2020



The recent advancements in immunotherapies, such as immune checkpoint modulators, bispecific antibodies, and adoptive T cell transfer, are shifting the way cancer patients are treated. Rapid development of novel immuno-oncology programs is creating the need for predictive preclinical models and translational strategies to understand combination immunotherapy, study responses and resistance to cancer immunotherapy, and identify novel biomarkers and targets. Please join Cambridge Healthtech Institute’s Fifth Annual Preclinical and Translational Immuno-Oncology meeting and learn about new clinically-relevant models for screening IO therapies and translational strategies to support clinical IO programs.

Preliminary Agenda

PRECLINICAL MODELS FOR IMMUNOTHERAPY

Translatability of Preclinical Models in Immuno-Oncology Drug Discovery

Mithun Khattar, PhD, Scientist II, Immuno-Oncology Lead, Takeda Oncology

Efficacy Testing and Mechanistic Studies in Patient-Derived Microtumor/Immune Cell Models

Christophe Sachse, PhD, Site Head Berlin, NMI TT Pharmaservices

Talk Title to be Announced

Zhao Chen, PhD, Lab Head, Exploratory Immuno-Oncology, Novartis Institute of Biomedical Research

MECHANISM OF RESPONSE AND RESISTANCE TO IMMUNOTHERAPY

Independent Contributions Account for Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies

Emmett Schmidt, PhD, Distinguished Scientist & Executive Director, Merck Research Labs

How a Blood-Clotting Protein and Blood Platelets Promote Immune Evasion, Cancer Progression

Zihai Li, MD, Founding Director, Pelotonia Institute for Immuno-Oncology; Professor, Translational Therapeutics Program, Internal Medicine, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James)

Deciphering the Function of B Cells in Human Cancer

Tullia C. Bruno, PhD, Assistant Professor, Immunology, University of Pittsburgh & Hillman Cancer Center

Talk Title to be Announced

Cara Haymaker, PhD, Assistant Professor; Director, Oncology Research and Immuno-Monitoring Core (ORION), Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center

Long-Term Outcomes and Responses to Retreatment in Melanoma Patients Treated with PD-1 Blockade

Allison Betof Warner, MD, PhD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center

PLENARY KEYNOTE SESSION

PD-1 Antibodies Either as Monotherapy or Precision Medicine Informed Combinations are Transforming Cancer Care

Roy Baynes, MD, PhD, Senior Vice President and Head, Global Clinical Development, CMO, Merck Research Laboratories

EMERGING CHECKPOINT INHIBITOR TARGETS: DISCOVERY, PRECLINICAL, AND TRANSLATIONAL APPROACHES

New Immune Checkpoints: From Discoveries to Clinical Trials

XingXing Zang, PhD, Professor and Louis Goldstein Swan Chair, Albert Einstein College of Medicine

TIM-3 Antibody for Immuno-Oncology

Xiaomo Jiang, PhD, Principle Scientist II, Immuno-Oncology, Novartis Institutes for BioMedical Research

Preclinical Identification and Validation of Immuno-Oncology Targets

Marcus Bosenberg, MD, PhD, Professor of Dermatology, Pathology, and Immunobiology; Interim Director, Yale Center for Immuno-Oncology; Director, Center for Precision Cancer Modeling, Yale University




For more details on the conference, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com

For partnering and sponsorship information, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com


Connect With Us

MEETING SUGGESTIONS

For meeting questions or suggestions, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
juliab@healthtech.com

PARTNERING & SPONSORSHIP

For partnering and sponsorship info, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
+1 781.247.6286
reymael@healthtech.com

MEDIA & ASSOCIATION

For media and association partnerships, please contact:

Pete DeOlympio
Sr. Marketing Manager
Cambridge Healthtech Institute
+1 781.972.5415
peted@healthtech.com